Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma

[1]  Yingying Zhang,et al.  Plasma membrane changes during programmed cell deaths , 2017, Cell Research.

[2]  A. Toker,et al.  AKT/PKB Signaling: Navigating the Network , 2017, Cell.

[3]  Leslie R Euceda,et al.  Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer Xenografts. , 2017, Journal of proteome research.

[4]  U. Banerji,et al.  Maximising the potential of AKT inhibitors as anti‐cancer treatments , 2017, Pharmacology & therapeutics.

[5]  Yuen-Li Chung.  Magnetic Resonance Spectroscopy (MRS)-Based Methods for Examining Cancer Metabolism in Response to Oncogenic Kinase Drug Treatment. , 2017, Methods in molecular biology.

[6]  Z. Bhujwalla,et al.  The Tumor Microenvironment Modulates Choline and Lipid Metabolism , 2016, Front. Oncol..

[7]  I. Fleming,et al.  Probing the PI3K/Akt/mTor pathway using 31P-NMR spectroscopy: routes to glycogen synthase kinase 3 , 2016, Scientific Reports.

[8]  N. Seki,et al.  Real‐Time GFP Intravital Imaging of the Differences in Cellular and Angiogenic Behavior of Subcutaneous and Orthotopic Nude‐Mouse Models of Human PC‐3 Prostate Cancer , 2016, Journal of cellular biochemistry.

[9]  Paul Workman,et al.  Drug discovery in advanced prostate cancer: translating biology into therapy , 2016, Nature Reviews Drug Discovery.

[10]  M. Cascante,et al.  Oncogenic regulation of tumor metabolic reprogramming , 2016, Oncotarget.

[11]  B. Krishnamachary,et al.  Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents , 2016, Front. Oncol..

[12]  A. Toker,et al.  Glutathione biosynthesis is a metabolic vulnerability in PI3K/Akt-driven breast cancer , 2016, Nature Cell Biology.

[13]  C. Thompson,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[14]  Q. Peng,et al.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review) , 2015, International journal of oncology.

[15]  J. Marshall,et al.  Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer , 2015, Scientific Reports.

[16]  A. Zoubeidi,et al.  Targeting the PI3K/Akt pathway in prostate cancer: challenges and opportunities (review). , 2014, International journal of oncology.

[17]  Martin O. Leach,et al.  Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers , 2014, Clinical Cancer Research.

[18]  Chris Jones,et al.  Lactate and Choline Metabolites Detected In Vitro by Nuclear Magnetic Resonance Spectroscopy Are Potential Metabolic Biomarkers for PI3K Inhibition in Pediatric Glioblastoma , 2014, PloS one.

[19]  T. Bathen,et al.  Quantitative 31P HR‐MAS MR spectroscopy for detection of response to PI3K/mTOR inhibition in breast cancer xenografts , 2014, Magnetic resonance in medicine.

[20]  C. Muñoz-Pinedo,et al.  Regulation of cancer metabolism by oncogenes and tumor suppressors. , 2014, Methods in enzymology.

[21]  Xue Meng,et al.  New strategy for monitoring targeted therapy: molecular imaging , 2013, International journal of nanomedicine.

[22]  Ralph J DeBerardinis,et al.  Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.

[23]  K. Coombes,et al.  KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. , 2013, Cancer research.

[24]  M. Brattain,et al.  Cell survival and metastasis regulation by Akt signaling in colorectal cancer. , 2013, Cellular signalling.

[25]  D. Cunningham,et al.  Targeting the PI3K-AKT-mTOR signaling network in cancer , 2013, Chinese journal of cancer.

[26]  P. N. Ragunath,et al.  Decreased lactate concentration and glycolytic enzyme expression reflect inhibition of mTOR signal transduction pathway in B‐cell lymphoma , 2013, NMR in biomedicine.

[27]  I. Gribbestad,et al.  Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer , 2013, Breast Cancer Research.

[28]  C. James,et al.  Reduced Phosphocholine and Hyperpolarized Lactate Provide Magnetic Resonance Biomarkers of Pi3k/akt/mtor Inhibition in Glioblastoma Neuro-onco Lo Gy , 2022 .

[29]  S. Ronen,et al.  Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells , 2012, NMR in biomedicine.

[30]  Kristen Scott,et al.  Hyperpolarized 13C MR spectroscopic imaging can be used to monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma , 2012, NeuroImage.

[31]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Leach,et al.  Exploiting tumor metabolism for non-invasive imaging of the therapeutic activity of molecularly targeted anticancer agents , 2011, Cell cycle.

[33]  I. Gribbestad,et al.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy , 2011, Molecular oncology.

[34]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[35]  R. Deberardinis,et al.  Glutamine: pleiotropic roles in tumor growth and stress resistance , 2011, Journal of Molecular Medicine.

[36]  Suzanne Naimi.  NAVIGATING the network , 2011 .

[37]  A. Rehemtulla,et al.  Molecular Imaging , 2009, Methods in Molecular Biology.

[38]  M. Leach,et al.  The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. , 2010, Cancer research.

[39]  W. Yung,et al.  Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. , 2010, Neuro-oncology.

[40]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[41]  M O Leach,et al.  Metabolic assessment of the action of targeted cancer therapeutics using magnetic resonance spectroscopy , 2009, British Journal of Cancer.

[42]  J. Galons,et al.  MRI‐measured water mobility increases in response to chemotherapy via multiple cell‐death mechanisms , 2007, NMR in biomedicine.

[43]  M. Waterfield,et al.  Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. , 2007, Cancer research.

[44]  J. G. Cory,et al.  Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. , 2006, In vivo.

[45]  Paul Workman,et al.  Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. , 2006, Journal of the National Cancer Institute.

[46]  Paul Workman,et al.  Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells , 2006, Molecular Cancer Therapeutics.

[47]  G. Collins.  The next generation. , 2006, Scientific American.

[48]  B. Sitter,et al.  High‐resolution magic angle spinning MRS of breast cancer tissue , 2002, NMR in biomedicine.

[49]  D. Gadian.  NMR and its Applications to Living Systems , 1996 .

[50]  H. Degani,et al.  Simultaneous extraction of cellular lipids and water‐soluble metabolites: Evaluation by NMR spectroscopy , 1996, Magnetic resonance in medicine.

[51]  A. Lee,et al.  Microvessel quantitation and prognosis in invasive breast carcinoma. , 1992, Human pathology.